Biotech

All Articles

OS Treatments refiles $6M IPO to cash HER2 medication, preclinical ADCs

.OS Therapies will certainly specify on the NYSE American inventory swap this morning through a $6.4...

ALX's fizzling CD47 response rate delivers stock spiraling down

.ALX Oncology's period 2 gastric cancer cells response rate has deteriorated. After finding its own ...

Ionis axes eye illness from intendeds of Roche-partnered prospect after information let down

.Yet Another of Ionis Pharmaceuticals' vital midphase readouts has actually disappointed expectation...

Biogen's chief executive officer pointed out no high-risk sell 2023. He's ready to become daring

.While Biogen's pharma peers are actually hunting for late-stage assets along with little risk, CEO ...

Instil refills pipe in $2B biobucks take care of ImmunOnco

.Instil Biography has been actually a biotech trying to find a pipe after it scrapped its lead prope...

Biogen ignores Denali Alzheimer's collab

.Biogen has restored rights to a very early Alzheimer's health condition system to Denali Therapies,...

Takeda faucets brand new mind of US oncology organization-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of substantial management hirings, shootings as ...

Vertex, beaten by AATD again, goes down 2 resources on throw out heap

.Tip's effort to treat a rare genetic condition has actually reached one more misfortune. The biotec...

Vir increases 3 T-cell engagers from Sanofi, lays off 25% of workers

.Vir Medical's second-quarter profits record wasn't except huge headlines. The firm accepted a triad...

Galapagos stops briefly CAR-T cell treatment litigation over Parkinsonism case

.Galapagos has stopped briefly enrollment in a test of a BCMA-directed CAR-T cell treatment, pushing...